Mechanism of diabetic neuropathy: Where are we now and where to go?
暂无分享,去创建一个
[1] S. Chung,et al. More severe type 2 diabetes‐associated ischemic stroke injury is alleviated in aldose reductase‐deficient mice , 2010, Journal of neuroscience research.
[2] E. Agardh,et al. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. , 2010, International journal of molecular medicine.
[3] Ravichandran Ramasamy,et al. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. , 2010, Circulation research.
[4] G. King,et al. Activation of protein kinase C isoforms and its impact on diabetic complications. , 2010, Circulation research.
[5] Ashutosh Kumar,et al. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. , 2010, Biochemical and biophysical research communications.
[6] S. Chung,et al. The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice , 2010, The Journal of pathology.
[7] G. Alton,et al. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. , 2010, Investigative ophthalmology & visual science.
[8] R. Wada,et al. Neuropathy induced by exogenously administered advanced glycation end‐products in rats , 2010, Journal of diabetes investigation.
[9] M. Boulton,et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock , 2009, The Journal of experimental medicine.
[10] E. Feldman,et al. Hyperlipidemia: a new therapeutic target for diabetic neuropathy , 2009, Journal of the peripheral nervous system : JPNS.
[11] K. Faulkner,et al. Sensory and Motor Peripheral Nerve Function and Lower‐Extremity Quadriceps Strength: The Health, Aging and Body Composition Study , 2009, Journal of The American Geriatrics Society.
[12] I. Obrosova. Diabetes and the peripheral nerve. , 2009, Biochimica et biophysica acta.
[13] J. Jakobsen,et al. Expression of neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength. , 2009, Brain : a journal of neurology.
[14] E. Agardh,et al. The Aldose Reductase Inhibitor Fidarestat Suppresses Ischemia-Reperfusion-Induced Inflammatory Response in Rat Retina , 2009, Pharmacology.
[15] Paul J Thornalley,et al. Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in Diabetes , 2009, Diabetes.
[16] Y. Yoon,et al. Bone Marrow Mononuclear Cells Have Neurovascular Tropism and Improve Diabetic Neuropathy , 2009, Stem cells.
[17] C. Sabanayagam,et al. Relationship between glycated haemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes? , 2009, Diabetologia.
[18] Thomas E. Lyons,et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. , 2009, The Journal of clinical endocrinology and metabolism.
[19] R. Pop-Busui,et al. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort , 2009, Journal of the peripheral nervous system : JPNS.
[20] P. Fernyhough,et al. Development of Selective Axonopathy in Adult Sensory Neurons Isolated From Diabetic Rats , 2009, Diabetes.
[21] Y. Yoon,et al. Dual Angiogenic and Neurotrophic Effects of Bone Marrow–Derived Endothelial Progenitor Cells on Diabetic Neuropathy , 2009, Circulation.
[22] R. Pop-Busui,et al. Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. , 2009, American journal of physiology. Heart and circulatory physiology.
[23] A. Quattrini,et al. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons , 2009, Diabetologia.
[24] T. Asano,et al. Regulation of Pancreatic β Cell Mass by Neuronal Signals from the Liver , 2008, Science.
[25] R. Kawamori,et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[26] M. Pietropaolo,et al. Stimulation of autophagy by autoantibody-mediated activation of death receptor cascades , 2008, Autophagy.
[27] P. Nawroth,et al. The RAGE Pathway , 2008, Annals of the New York Academy of Sciences.
[28] W. Liu,et al. Receptor for Advanced Glycation End Products (RAGEs) and Experimental Diabetic Neuropathy , 2008, Diabetes.
[29] S. Yagihashi,et al. Role of advanced glycation end products in diabetic neuropathy. , 2008, Current pharmaceutical design.
[30] R. Wada,et al. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated‐γ‐ligand, in insulin‐deficient diabetic rats , 2007, Journal of neurochemistry.
[31] Koichi Kato. The pathogenesis of diabetic neuropathy , 2008 .
[32] J. Groves,et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. , 2007, American journal of physiology. Endocrinology and metabolism.
[33] D. Zochodne,et al. RAGE, diabetes, and the nervous system. , 2007, Current molecular medicine.
[34] S. Chung,et al. Gene deletion and pharmacological inhibition of aldose reductase protect against retinal ischemic injury. , 2007, Experimental eye research.
[35] J. Nadler,et al. High-Fat Diet–Induced Neuropathy of Pre-Diabetes and Obesity , 2007, Diabetes.
[36] Soroku Yagihashi,et al. Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. , 2007, Diabetes research and clinical practice.
[37] G. Ryan. New pharmacologic approaches to treating diabetic retinopathy. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[38] Nathan Efron,et al. Surrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy , 2007, Diabetes.
[39] S. Sharma,et al. Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. , 2007, European journal of pharmacology.
[40] N. Calcutt,et al. Pathogenesis of Spinally Mediated Hyperalgesia in Diabetes , 2007, Diabetes.
[41] M. Mata,et al. Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer , 2007, Diabetologia.
[42] R. Dobrowsky,et al. Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice , 2007, Neuroscience.
[43] G. Cavaletti,et al. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: A multimodal analysis , 2007, Neuroscience.
[44] A. Sastry,et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. , 2007, Endocrinology.
[45] A. Vinik,et al. Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.
[46] Fei Li,et al. The Leptin-Deficient (ob/ob) Mouse , 2006, Diabetes.
[47] E. Feldman,et al. Mechanisms of Disease: mitochondria as new therapeutic targets in diabetic neuropathy , 2006, Nature Clinical Practice Neurology.
[48] S. Kusunoki,et al. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat , 2006, Diabetologia.
[49] H. Kamiya,et al. Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats , 2006, Diabetologia.
[50] P. Low,et al. Enhanced inflammatory response via activation of NF-κB in acute experimental diabetic neuropathy subjected to ischemia–reperfusion injury , 2006, Journal of the Neurological Sciences.
[51] R. Pop-Busui,et al. Diabetic neuropathy and oxidative stress , 2006, Diabetes/metabolism research and reviews.
[52] R. Kawamori,et al. Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy , 2006, Diabetes Care.
[53] S. Chung,et al. Aldose Reductase–Deficient Mice Are Protected From Delayed Motor Nerve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage , 2006, Diabetes.
[54] Y. Sunada,et al. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice , 2006, The journal of gene medicine.
[55] Lei Zhang,et al. Gene Transfer of an Engineered Transcription Factor Promoting Expression of VEGF-A Protects Against Experimental Diabetic Neuropathy , 2006, Diabetes.
[56] M. Stevens,et al. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. , 2006, Free radical biology & medicine.
[57] R. Wada,et al. Prolonged ischemic conduction failure after reperfusion in diabetic nerve , 2006, Muscle & nerve.
[58] James Albers,et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. , 2006, Diabetes care.
[59] C. Yabe-Nishimura,et al. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. , 2006, Journal of pharmacological sciences.
[60] P. Hossain,et al. Early detection of diabetic peripheral neuropathy with corneal confocal microscopy , 2005, The Lancet.
[61] T. Sasase,et al. Novel protein kinase C‐β isoform selective inhibitor JTT‐010 ameliorates both hyper‐ and hypoalgesia in streptozotocin‐ induced diabetic rats , 2005, Diabetes, obesity & metabolism.
[62] M. Fujimiya,et al. The fusion of bone-marrow-derived proinsulin-expressing cells with nerve cells underlies diabetic neuropathy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[63] A. Verkhratsky,et al. Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats , 2005, Experimental Neurology.
[64] R. Wada,et al. Role of Advanced Glycation End Products and Their Receptors in Development of Diabetic Neuropathy , 2005, Annals of the New York Academy of Sciences.
[65] M. Nangle,et al. Inhibitors of Advanced Glycation End Product Formation and Neurovascular Dysfunction in Experimental Diabetes , 2005, Annals of the New York Academy of Sciences.
[66] H. Sone,et al. Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.
[67] E. Schleicher,et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[68] S. Shaw,et al. Aldose reductase pathway mediates JAK‐STAT signaling: a novel axis in myocardial ischemic injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[69] E. Feldman,et al. Short‐term hyperglycemia produces oxidative damage and apoptosis in neurons , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[70] Dan Ziegler,et al. Diabetic neuropathies: a statement by the American Diabetes Association. , 2005, Diabetes care.
[71] D. Zochodne,et al. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? , 2005, Diabetes.
[72] W. Köpcke,et al. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). , 2005, International journal of clinical pharmacology and therapeutics.
[73] C. Szabó,et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. , 2005, Diabetes.
[74] P. K. Thomas,et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy , 2005, Diabetologia.
[75] J. Schneider,et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. , 2004, The Journal of clinical investigation.
[76] S. Yagihashi,et al. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. , 2004, Diabetes.
[77] Fei Li,et al. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. , 2004, American journal of physiology. Endocrinology and metabolism.
[78] S. Yagihashi,et al. Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. , 2004, Biochemical and biophysical research communications.
[79] Justin C McArthur,et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. , 2004, Brain : a journal of neurology.
[80] Whei-Min Lin,et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. , 2004, Brain : a journal of neurology.
[81] Fei Li,et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. , 2004, Diabetes.
[82] R. Wada,et al. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine , 1996, Diabetologia.
[83] M. Cotter,et al. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats , 1993, Diabetologia.
[84] P. Thomas,et al. Pattern of myelinated fibre loss in the sural nerve in neuropathy related to Type 1 (insulin-dependent) diabetes , 1988, Diabetologia.
[85] P. K. Thomas,et al. Abnormal innervation of lower limb epineurial arterioles in human diabetes , 2004, Diabetologia.
[86] S. Yagihashi,et al. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice , 2003, Journal of neurochemistry.
[87] K. Eriksson,et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. , 2003, Diabetes.
[88] A. Vinik,et al. Nerve Growth Factor and Diabetic Neuropathy , 2003, Experimental diabesity research.
[89] R. Neubig,et al. Diabetic neuropathy: inhibitory G protein dysfunction involves PKC‐dependent phosphorylation of Goα , 2003, Journal of neurochemistry.
[90] N. Calcutt,et al. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. , 2003, Diabetes.
[91] P. Fernyhough,et al. Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. , 2003, Brain : a journal of neurology.
[92] R. A. Malik,et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients , 2003, Diabetologia.
[93] S. Yagihashi,et al. The Possible Role of Tumor Necrosis Factor-α in Diabetic Polyneuropathy , 2003, Experimental diabesity research.
[94] N. Hotta,et al. Polyol pathway and protein kinase C activity of rat Schwannoma cells , 2003, Diabetes/metabolism research and reviews.
[95] D. Wright,et al. Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice , 2003, Experimental Neurology.
[96] C. Sumner,et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance , 2003, Neurology.
[97] A. Kashiwagi,et al. Amelioration of retarded neurite outgrowth of dorsal root ganglion neurons by overexpression of PKCdelta in diabetic rats. , 2003, Neuroreport.
[98] R. Pop-Busui,et al. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. , 2002, Diabetes.
[99] M. Cotter,et al. Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism , 2002, Diabetes/metabolism research and reviews.
[100] E. Scarpini,et al. Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1β and p75NTR , 2002, Journal of the Neurological Sciences.
[101] P. McMorran,et al. Aggravated reperfusion injury in STZ‐diabetic nerve , 2002, Journal of the peripheral nervous system : JPNS.
[102] D. Greene,et al. An aldose reductase inhibitor reverses early diabetes‐induced changes in peripheral nerve function, metabolism, and antioxidative defense , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[103] Paul J Thornalley. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. , 2002, International review of neurobiology.
[104] G. King,et al. Protein kinase C and the development of diabetic vascular complications , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[105] R. Wada,et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. , 2001, Brain : a journal of neurology.
[106] S. Tripp,et al. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy , 2001, Neurology.
[107] R. Wada,et al. Effects of OPB‐9195, anti‐glycation agent, on experimental diabetic neuropathy , 2001, European journal of clinical investigation.
[108] S. Yagihashi,et al. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients , 2001, Virchows Archiv.
[109] R. Schmidt,et al. Effect of NGF and Neurotrophin‐3 Treatment on Experimental Diabetic Autonomic Neuropathy , 2001, Journal of neuropathology and experimental neurology.
[110] D. Greene,et al. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. , 2000, Diabetes.
[111] H. Tritschler,et al. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. , 1999, Diabetes.
[112] A. Boulton,et al. Structural abnormalities do not explain the early functional abnormalities in the peripheral nerves of the streptozotocin diabetic rat , 1999, Journal of anatomy.
[113] N. Hotta,et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. , 1999, Diabetes.
[114] D. Tomlinson. Mitogen-activated protein kinases as glucose transducers for diabetic complications , 1999, Diabetologia.
[115] S. Apfel. Neurotrophic factors in the therapy of diabetic neuropathy. , 1999, The American journal of medicine.
[116] E. Feldman,et al. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. , 1999, European journal of pharmacology.
[117] J. Riggs. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. , 1998, Neurology.
[118] M. Cronin,et al. Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. , 1998, Diabetes.
[119] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[120] W. Litchy,et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy , 1998, Neurology.
[121] S. Yagihashi,et al. Localization in human diabetic peripheral nerve of Nɛ-carboxymethyllysine-protein adducts, an advanced glycation endproduct , 1997, Diabetologia.
[122] P. Fernyhough,et al. Role of Neurotrophins in Diabetic Neuropathy and Treatment with Nerve Growth Factors , 1997, Diabetes.
[123] M. Pfeifer,et al. Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs? , 1997, Diabetes.
[124] R. Wada,et al. Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. , 1997, Journal of diabetes and its complications.
[125] M. Donaghy,et al. Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus , 1997, Muscle & nerve.
[126] S. Yagihashi,et al. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. , 1997, Microvascular research.
[127] E. Feldman,et al. Pathogenesis of diabetic neuropathy. , 1989, Clinical neuroscience.
[128] S. Yagihashi,et al. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. , 1997, Diabetologia.
[129] P. Dyck,et al. Pathologic Alterations in the Diabetic Neuropathies of Humans: A Review , 1996, Journal of neuropathology and experimental neurology.
[130] G. Wendelschafer‐Crabb,et al. Quantitation of epidermal nerves in diabetic neuropathy , 1996, Neurology.
[131] D. Zochodne. Neurotrophins and Other Growth Factors in Diabetic Neuropathy , 1996, Seminars in neurology.
[132] G. Rosoklija,et al. Diabetic peripheral neuropathy: A clinicopathologic and immunohistochemical analysis of sural nerve biopsies , 1996, Muscle & nerve.
[133] P. Kopelman,et al. The role of endogenous nerve growth factor in human diabetic neuropathy , 1996, Nature Medicine.
[134] R. Wada,et al. Galactosemic Neuropathy in Transgenic Mice for Human Aldose Reductase , 1996, Diabetes.
[135] M. Hanefeld,et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). , 1995, Diabetologia.
[136] J. McArthur,et al. Cutaneous innervation in sensory neuropathies , 1995, Neurology.
[137] S. Yagihashi,et al. Pathology and pathogenetic mechanisms of diabetic neuropathy. , 1995, Diabetes/metabolism reviews.
[138] E. Araki,et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.
[139] N. Hotta,et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[140] J. Arezzo,et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy , 1994, Brain Research.
[141] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[142] M. Cotter,et al. Potential Therapeutic Approaches to the Treatment or Prevention of Diabetic Neuropathy: Evidence from Experimental Studies , 1993, Diabetic medicine : a journal of the British Diabetic Association.
[143] E. Feldman,et al. Complications: Neuropathy, Pathogenetic Considerations , 1992, Diabetes Care.
[144] C J Watkins,et al. Innervation of the Vasa Nervorum: Changes in Human Diabetics , 1992, Journal of neuropathology and experimental neurology.
[145] S. Yagihashi,et al. Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.
[146] D. Greene,et al. Endoneurial Microvessels in Human Diabetic Neuropathy: Endothelial Cell Dysjunction and Lack of Treatment Effect by Aldose Reductase Inhibitor , 1991, Diabetes.
[147] P. Low,et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[148] P. Low,et al. Endoneurial blood flow in rat sciatic nerve during development. , 1991, The Journal of physiology.
[149] R. Hellweg,et al. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy , 1990, Journal of neuroscience research.
[150] J. Kinoshita,et al. A thirty year journey in the polyol pathway. , 1990, Experimental eye research.
[151] T. Vilén,et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. , 1988, The New England journal of medicine.
[152] W W Monafo,et al. Regional blood flow in sciatic nerve, biceps femoris muscle, and truncal skin in response to hemorrhagic hypotension. , 1987, The Journal of trauma.
[153] D. Greene,et al. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. , 1987, The New England journal of medicine.
[154] P. Dyck,et al. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia , 1986, Annals of neurology.
[155] P. Wagner. Gas exchange in chronic pulmonary disease. , 1985, Clinical physiology.
[156] J. Jakobsen,et al. Nerve morphology in experimental diabetes , 1985, Clinical physiology.
[157] P J Dyck,et al. Spatial pattern of nerve fiber abnormality indicative of pathologic mechanism. , 1984, The American journal of pathology.
[158] P. Dyck,et al. Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry , 1980, Annals of neurology.
[159] Clarke Bf,et al. Prognosis in diabetic autonomic neuropathy. , 1980 .
[160] D. Ewing,et al. The natural history of diabetic autonomic neuropathy. , 1980, The Quarterly journal of medicine.
[161] S. Yagihashi,et al. Ultrastructural pathology of peripheral nerves in patients with diabetic neuropathy. , 1979, The Tohoku journal of experimental medicine.
[162] J. Pirart. Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973 , 1978, Diabetes Care.
[163] A. Kobrine,et al. Absence of autoregulation in peripheral nerve blood flow , 1977, Journal of the Neurological Sciences.
[164] D. Ewing,et al. MORTALITY IN DIABETIC AUTONOMIC NEUROPATHY , 1976, The Lancet.
[165] K. Gabbay,et al. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. , 1975, Annual review of medicine.